The FDA is transferring at breakneck pace to roll out a generative synthetic intelligence (AI) software for rushing up regulatory critiques, saying its launch practically a month forward of the thirtieth June deadline.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased
